JP6209210B2 - 神経変性疾患の処置のために有用なスピロテトラヒドロ−ベンゾチオフェン誘導体 - Google Patents

神経変性疾患の処置のために有用なスピロテトラヒドロ−ベンゾチオフェン誘導体 Download PDF

Info

Publication number
JP6209210B2
JP6209210B2 JP2015514375A JP2015514375A JP6209210B2 JP 6209210 B2 JP6209210 B2 JP 6209210B2 JP 2015514375 A JP2015514375 A JP 2015514375A JP 2015514375 A JP2015514375 A JP 2015514375A JP 6209210 B2 JP6209210 B2 JP 6209210B2
Authority
JP
Japan
Prior art keywords
formula
compound
mmol
thiophene
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015514375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521192A5 (https=
JP2015521192A (ja
Inventor
クアトロパーニ，アンナ
スウィンネン，ドミニク
Original Assignee
アレス トレーディング ソシエテ アノニム
アレス トレーディング ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレス トレーディング ソシエテ アノニム, アレス トレーディング ソシエテ アノニム filed Critical アレス トレーディング ソシエテ アノニム
Publication of JP2015521192A publication Critical patent/JP2015521192A/ja
Publication of JP2015521192A5 publication Critical patent/JP2015521192A5/ja
Application granted granted Critical
Publication of JP6209210B2 publication Critical patent/JP6209210B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015514375A 2012-05-31 2013-05-10 神経変性疾患の処置のために有用なスピロテトラヒドロ−ベンゾチオフェン誘導体 Expired - Fee Related JP6209210B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12170227.8 2012-05-31
EP20120170227 EP2669286A1 (en) 2012-05-31 2012-05-31 Spiro tetrahydro-benzothiophen derivatives useful for the treatment of neurodegenerative diseases
US201261655078P 2012-06-04 2012-06-04
US61/655,078 2012-06-04
PCT/EP2013/001389 WO2013178322A1 (en) 2012-05-31 2013-05-10 Spiro tetrahydro - benzothiophen derivatives useful for the treatment neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2015521192A JP2015521192A (ja) 2015-07-27
JP2015521192A5 JP2015521192A5 (https=) 2017-09-14
JP6209210B2 true JP6209210B2 (ja) 2017-10-04

Family

ID=46210136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514375A Expired - Fee Related JP6209210B2 (ja) 2012-05-31 2013-05-10 神経変性疾患の処置のために有用なスピロテトラヒドロ−ベンゾチオフェン誘導体

Country Status (9)

Country Link
US (1) US9233982B2 (https=)
EP (2) EP2669286A1 (https=)
JP (1) JP6209210B2 (https=)
CN (1) CN104364258B (https=)
AU (1) AU2013269996B2 (https=)
CA (1) CA2875132C (https=)
ES (1) ES2581540T3 (https=)
IL (1) IL235955B (https=)
WO (1) WO2013178322A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518048A (ja) 2012-05-30 2015-06-25 コメンティス， インコーポレイテッド クロマン化合物
US9580396B2 (en) 2012-12-21 2017-02-28 Merck Sharp & Dohme Corp. C6-spiro iminothiadiazine dioxides as BACE inhibitors, compositions, and their use
WO2015038446A1 (en) 2013-09-13 2015-03-19 Merck Sharp & Dohme Corp. C5-spiro iminothiazine dioxides as bace inhibitors, compositions, and their use
EP3201204B1 (en) 2014-10-03 2021-02-24 Merck Sharp & Dohme Corp. C5-c6-fused tricyclic iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
KR102114536B1 (ko) 2015-05-07 2020-05-22 브리스톨-마이어스 스큅 컴퍼니 RORγ 조정제로서의 트리시클릭 술폰
EP3523279A1 (en) 2016-10-10 2019-08-14 Bristol-Myers Squibb Company Tricyclic sulfones as ror gamma modulators
JP6785965B2 (ja) * 2017-06-14 2020-11-18 日本曹達株式会社 オキサジアゾリン化合物および有害生物防除剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
TWI391385B (zh) * 2006-07-18 2013-04-01 Astellas Pharma Inc An amine-based indane derivative or a salt thereof
EP2151435A4 (en) * 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2318416B1 (en) 2008-07-28 2013-09-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
JP5444240B2 (ja) * 2008-07-28 2014-03-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
CA2753730C (en) * 2009-03-13 2020-12-22 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
CN102812005B (zh) * 2010-02-24 2014-12-10 生命医药公司 β-分泌酶抑制剂
US20120065195A1 (en) * 2010-03-31 2012-03-15 Clark Christopher T Compounds for treating neurodegenerative diseases

Also Published As

Publication number Publication date
EP2855486A1 (en) 2015-04-08
WO2013178322A1 (en) 2013-12-05
AU2013269996B2 (en) 2017-04-13
CA2875132A1 (en) 2013-12-05
CN104364258B (zh) 2017-05-24
ES2581540T3 (es) 2016-09-06
IL235955B (en) 2018-06-28
WO2013178322A8 (en) 2014-12-11
CA2875132C (en) 2020-07-28
CN104364258A (zh) 2015-02-18
IL235955A0 (en) 2015-02-01
EP2855486B1 (en) 2016-04-06
US9233982B2 (en) 2016-01-12
EP2669286A1 (en) 2013-12-04
AU2013269996A1 (en) 2015-01-22
JP2015521192A (ja) 2015-07-27
US20150111882A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
JP7299382B2 (ja) Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
JP6209210B2 (ja) 神経変性疾患の処置のために有用なスピロテトラヒドロ−ベンゾチオフェン誘導体
CN111278815B (zh) 戊二酰亚胺
CN115215886B (zh) 作为内体Toll样受体抑制剂的化合物及组合物
JP5680082B2 (ja) β−アミロイド産生低減のための化合物
CN105814045B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
CN101983059B (zh) 2,3,4,5- 四氢 -1h- 吡啶并 [4,3-b] 吲哚化合物及其使用方法
TW202425987A (zh) 作為免疫調節劑之雜環化合物
US20240101563A1 (en) Novel compounds
KR102531689B1 (ko) ６，７―디히드로피라졸로［１，５―α］피라진―４（５Ｈ）―온 화합물 및 ＭＧＬＵＲ２ 수용체의 음성 알로스테릭 조절제로서의 그 용도
CA3219215A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
US20160289230A1 (en) Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same
JP6517340B2 (ja) ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用
TW201300381A (zh) 用於降低β－類澱粉製造之化合物
US10112944B2 (en) Heterocyclic compounds useful as inhibitors of TNF
JP7178357B2 (ja) オキサジアゾール一過性受容器電位チャネル阻害剤
US9527853B2 (en) Fused triazole derivatives as gamma secretase modulators
EP3258929B1 (en) Factor ixa inhibitors
TW202317087A (zh) 用於治療與sting活性相關病況之化合物及組合物
JP2021512942A (ja) トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびｍＧｌｕ５受容体のモジュレータとしてのそれらの使用
EA045073B1 (ru) Производные хромена в качестве ингибиторов взаимодействия tcr-nck

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160509

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170727

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170908

R150 Certificate of patent or registration of utility model

Ref document number: 6209210

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees